Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00055_DB01109_nanopub.RA24xdebiLpO7xcX3wUJTAMnlxztQ00HGlR9JzWmwgFIs#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00055_DB01109 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00055_DB01109 label "DDI between Drotrecogin alfa and Heparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. [drugbank_resource:DB00055_DB01109]" assertion.
- drugbank_resource:DB00055_DB01109 identifier "drugbank_resource:DB00055_DB01109" assertion.
- drugbank_resource:DB00055_DB01109 title "DDI between Drotrecogin alfa and Heparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin." assertion.
- drugbank:DB01109 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00055_DB01109 assertion.
- drugbank:DB00055 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00055_DB01109 assertion.